BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates
ONC•Sonrotoclax approval updates
Sonrotoclax (BEQALZI) was cited as approved in the U.S. for relapsed or refractory mantle cell lymphoma.
Sonrotoclax was also cited as approved in China for relapsed or refractory mantle cell lymphoma and relapsed or refractory chronic lymphocytic leukemia.
Pipeline and clinical stage snapshot
BeOne highlighted a pipeline snapshot with 35+ clinical or commercial-stage assets across hematology, solid tumors, inflammation and immunology.
New trial entries and pivotal study update
The pipeline update flagged new Phase 1/Ib entries for BG-75202-102 in myeloid malignancies and BON-110-101 in solid tumors.
It also flagged BGB-43395-302 as entering a pivotal trial in first-line HR+/HER2- breast cancer.
